2Strands is an early-stage precision diagnostics company developing blood-based monitoring tests for cancer patients.
Early cancer recurrence detection remains challenging, as imaging often identifies relapse too late, while existing ctDNA tests are either costly or lack sufficient sensitivity to detect the earliest signs of recurrence.
Our proprietary rare variant enrichment technology selectively concentrates mutant alleles prior to sequencing — decoupling sensitivity from sequencing depth.
2Strands Recura is an innovative blood test for accurate and affordable Minimal Residual Disease (MRD) monitoring.
Powered by 2Strands Biosciences' proprietary allele enrichment technology, 2Strands Recura selectively enriches target mutations while depleting non-target alleles.
This reduces sequencing requirements, enables detection of multiple low-frequency mutations, and helps balance cost, sensitivity, and specificity to better guide treatment decisions and improve patient outcomes.
The 2Strands Biosciences team brings together extensive expertise in molecular biology, Genomics and Assay Development. Our multidisciplinary team is dedicated to advancing highly sensitive and cost-effective ctDNA technologies for early minimal residual disease (MRD) detection and precision cancer monitoring.
We are always on a lookout for driven and outstanding candidates with experience in assay development, NGS bioinformatics, and Medtech development. For enquires about a role or internship opportunities, kindly fill up the contact form below.
Get in touch →If you'd like to get in touch with us, please fill up the contact form below.